Elcelyx Therapeutics Company

Elcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx’s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets. Elcelyx is headquartered in San Diego, California.
Technology: Small Molecules
Industry: PharmTech
Headquarters: San Diego
Founded Date: 2010-01-01
Employees Number: 11-50
Funding Status: Late Stage Venture
Investors Number: 7
Total Funding: $96,845,109
Estimated Revenue: $1M to $10M
Last Funding Type: Series E

Visit Website
Register and Claim Ownership